TuHURA Biosciences Reports Q3 2025 Results and Advances Phase 3 IFx-2.0 Trial

Reuters

2025/11/14

TuHURA Biosciences Reports Q3 2025 Results and Advances Phase 3 IFx-2.0 Trial

TuHURA Biosciences, Inc. (NASDAQ:HURA) reported its financial results for the third quarter ended September 30, 2025. Net cash outflows from operating activities were $22.1 million for the nine months ended September 30, 2025, compared to $12.1 million for the same period in 2024. As of September 30, 2025, the company had approximately 51.2 million total shares outstanding. The company provided a corporate update, noting that its Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) for advanced and metastatic Merkel cell carcinoma is underway under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. TuHURA's Delta Opioid Receptor (DOR) technology was selected for an oral presentation and two poster presentations at the 67th Annual American Society of Hematology Annual Meeting in December 2025. Additionally, TuHURA appointed Dr. Michael Turner as Vice President of Immunology in November 2025 and filed a $50 million At-The-Market facility following eligibility to file a shelf registration statement on Form S-3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA24219) on November 14, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583508058"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583508058\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583508058?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583508058","market":"fut","top_or_hot":-1,"title":"TuHURA Biosciences Reports Q3 2025 Results and Advances Phase 3 IFx-2.0 Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TuHURA Biosciences Reports Q3 2025 Results and Advances Phase 3 IFx-2.0 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences, Inc.</a> (NASDAQ:HURA) reported its financial results for the third quarter ended September 30, 2025. Net cash outflows from operating activities were $22.1 million for the nine months ended September 30, 2025, compared to $12.1 million for the same period in 2024. As of September 30, 2025, the company had approximately 51.2 million total shares outstanding. The company provided a corporate update, noting that its Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) for advanced and metastatic Merkel cell carcinoma is underway under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. TuHURA's Delta Opioid Receptor (DOR) technology was selected for an oral presentation and two poster presentations at the 67th Annual American Society of Hematology Annual Meeting in December 2025. Additionally, TuHURA appointed Dr. Michael Turner as Vice President of Immunology in November 2025 and filed a $50 million At-The-Market facility following eligibility to file a shelf registration statement on Form S-3.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA24219) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TuHURA Biosciences Reports Q3 2025 Results and Advances Phase 3 IFx-2.0 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTuHURA Biosciences Reports Q3 2025 Results and Advances Phase 3 IFx-2.0 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TuHURA Biosciences Reports Q3 2025 Results and Advances Phase 3 IFx-2.0 Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/HURA\">TuHURA Biosciences, Inc.</a> (NASDAQ:HURA) reported its financial results for the third quarter ended September 30, 2025. Net cash outflows from operating activities were $22.1 million for the nine months ended September 30, 2025, compared to $12.1 million for the same period in 2024. As of September 30, 2025, the company had approximately 51.2 million total shares outstanding. The company provided a corporate update, noting that its Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) for advanced and metastatic Merkel cell carcinoma is underway under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. TuHURA's Delta Opioid Receptor (DOR) technology was selected for an oral presentation and two poster presentations at the 67th Annual American Society of Hematology Annual Meeting in December 2025. Additionally, TuHURA appointed Dr. Michael Turner as Vice President of Immunology in November 2025 and filed a $50 million At-The-Market facility following eligibility to file a shelf registration statement on Form S-3.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA24219) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL74blBd:1","article_id":"2583508058","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583508058","pubTimestamp":1763121674,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TuHURA Biosciences, Inc.  reported its financial results for the third quarter ended September 30, 2025. Net cash outflows from operating activities were $22.1 million for the nine months ended September 30, 2025, compared to $12.1 million for the same period in 2024. As of September 30, 2025, the company had approximately 51.2 million total shares outstanding. The company provided a corporate update, noting that its Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda  for advanced and metastatic Merkel cell carcinoma is underway under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. TuHURA's Delta Opioid Receptor  technology was selected for an oral presentation and two poster presentations at the 67th Annual American Society of Hematology Annual Meeting in December 2025. Additionally, TuHURA appointed Dr. Michael Turner as Vice President of Immunology in November 2025 and filed a $50 million At-The-Market facility follo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HURA":"TuHURA Biosciences, Inc."},"translate_title":"TuHURA Biosciences报告2025年第三季度结果和3期IFx-2.0试验进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HURA":0.9},"content_text":"TuHURA Biosciences Reports Q3 2025 Results and Advances Phase 3 IFx-2.0 Trial\n    \n\nTuHURA Biosciences, Inc. (NASDAQ:HURA) reported its financial results for the third quarter ended September 30, 2025. Net cash outflows from operating activities were $22.1 million for the nine months ended September 30, 2025, compared to $12.1 million for the same period in 2024. As of September 30, 2025, the company had approximately 51.2 million total shares outstanding. The company provided a corporate update, noting that its Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) for advanced and metastatic Merkel cell carcinoma is underway under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. TuHURA's Delta Opioid Receptor (DOR) technology was selected for an oral presentation and two poster presentations at the 67th Annual American Society of Hematology Annual Meeting in December 2025. Additionally, TuHURA appointed Dr. Michael Turner as Vice President of Immunology in November 2025 and filed a $50 million At-The-Market facility following eligibility to file a shelf registration statement on Form S-3.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA24219) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}